1741P Malignant effusion-derived non-small cell lung cancer organoid might be a feasible in vitro model for therapeutic screening

Abstract

In this single-center, retrospective study we evaluated clinicopathological features, frontline treatment and survival outcomes of 63 patients with an ascertained pathological diagnosis of SM treated in our center from 2000 until 2020.Results: The median age was 71 years (range 45-88), 57 (90%) patients were male. At the time of diagnosis, 52 (83%) patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) 1. Twenty (32%) patients received best supportive care (BSC), 39 (62%) received first-line chemotherapy (CT), 3 (5%) trimodality treatment and 1 (2%) patient underwent surgery only. In the subgroup of patients with first-line CT, 26 (67%) were treated with a platinum-based doublet-CT, while 13 (33%) received single agent CT (mono-CT). Patients treated with CT had a median progression-free survival (PFS) of 2 months (95% confidence interval (CI) 1.24-2.76) and a median OS of 7 months (95% CI 5.26-8.74). Compared with patients with mono-CT, patients receiving doublet-CT had a longer median OS (3 months vs. 8 months, HR 0.42 [95% CI, 0.21-0.85], p¼0.009). The median PFS was 3 months for patients receiving doublet-CT and 1 month for patients treated with mono-CT (HR 0.87 [95% CI 0.43-1.74], p¼0.63) The median OS of patients receiving BSC was 2 months (95% CI 0.95-3.05). No significant difference in OS was found when comparing mono-CT with BSC (3 vs. 2 months, HR 0.55 [95% CI, 0.26-1.17], p¼0.082) and this was consistent in the subgroup of patients aged 70 years (OS 3 vs. 2 months, HR 0.73 [95% CI 0.3-1.75], p¼0.440).Conclusions: In patients with SM not eligible for frontline platinum-based doublet-CT, treatment with single agent CT should be carefully evaluated, since the survival benefit is unclear. abstracts Annals of Oncology Volume 32 -Issue S5 -2021 S1203

Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer

“…They also show a high degree of consistency with clinical specimens in genotype and phenotype, exhibit a response to antitumor drugs, and are available in a short period of time. [23][24][25] The establishment of tumor PDOs for the screening of antitumor drugs provides a powerful reference for clinical treatment.…”

“…Patient‐derived organoids (PDOs) are 3‐dimensional (3D) organotypic structures, which can perfectly recapitulate the heterogeneity and diversity of tumors. They also show a high degree of consistency with clinical specimens in genotype and phenotype, exhibit a response to antitumor drugs, and are available in a short period of time 23–25 . The establishment of tumor PDOs for the screening of antitumor drugs provides a powerful reference for clinical treatment.…”